Objectif
Amyotrophic Lateral Sclerosis is one of the most devastating diseases in neurology affecting in Europe 50,000 individuals at any time, and causing around 10,000 deaths each year. ALS is characterized by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS affects otherwise healthy people at any time in adulthood. The patient becomes paralyzed and dies as the result of respiratory failure on average 3 years after onset of symptoms. There is no cure for ALS. The only available drug (Riluzole) is marginally effective in extending the lifespan of ALS patients with 3 to 6 months.
Despite recent scientific breakthroughs in the discovery of (1) multiple ALS associated genes, (2) evidence for metabolic dysregulation, (3) environmental risk factors, and (4) the protein TDP43 in aggregates of 95% of ALS patients, mechanistic models applicable to patients are still unknown. This shows that ALS can best be tackled through a systems biology approach which can only be achieved in a large integrative effort at the European level.
Euro-MOTOR unites a multidisciplinary partnership of world-leading experts of clinicians, basic scientists and bioinformaticians, and is able to exploit excellent infrastructures for patient sampling, -omics platforms, disease modelling and bioinformatics. Euro-MOTOR will integrate large quantitative -omics data sets from new functional models and from patients in two prospective European, population-based inception cohorts. By leveraging on the variation in the multilevel -omics data, Euro-MOTOR aims to detect key genetic drivers of disease susceptibility/progression, while parametric modelling of the causal connections in identified molecular networks will generate a model of disease. Major findings will be validated in a second prospective patient cohort and adequate functional models, resulting in robust targets that pave the way for novel therapeutic interventions for this disabling and fatal disease.
Champ scientifique
Appel à propositions
FP7-HEALTH-2010-two-stage
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
3584 CX Utrecht
Pays-Bas
Voir sur la carte
Participants (14)
9052 ZWIJNAARDE - GENT
Voir sur la carte
75012 Paris
Voir sur la carte
67081 Strasbourg
Voir sur la carte
89081 Ulm
Voir sur la carte
80539 Munchen
Voir sur la carte
97080 Wurzburg
Voir sur la carte
D02 CX56 DUBLIN 2
Voir sur la carte
20156 Milano
Voir sur la carte
10124 Torino
Voir sur la carte
9713 GZ Groningen
Voir sur la carte
WC2R 2LS London
Voir sur la carte
WC1E 6BT LONDON
Voir sur la carte
S10 2TN Sheffield
Voir sur la carte
SW7 2AZ LONDON
Voir sur la carte